Tag: investment
-
Venture Funding Down in 2Q, Health Companies Score in Exits
Venture capital (VC) funding of start-up companies in the U.S. continued its decline in the second quarter of 2013, but biotechnology start-ups figured prominently in gaining liquidity during that quarter. The data, compiled by the investment industry research service Dow Jones VentureSource, shows U.S. companies raised $7.2 billion in 801 deals during the second quarter, registering declines…
-
University Research Leads to Non-Toxic Insect Repellant
Research by an entomology professor at University of California in Riverside led to a company licensing his discoveries that announced its first product, a non-toxic patch that repels mosquitoes for 48 hours. Olfactor Laboratories, a company co-founded by and licensing the research of Anandasankar Ray, makes the Kite mosquito patch, which yesterday started a crowd-funding…
-
Stem Cell Developer-Supplier Issues Initial Public Offering
Cellular Dynamics International in Madison, Wisconsin, a developer and supplier of human stem cells in bulk quantities, filed an initial public offering (IPO) of its stock with the U.S. Securities and Exchange Commission. The company is issuing some 3.85 million shares, which it expects to price at $12.00 to $14.00 a share, giving it an…
-
Alternative Solar Cell Developer Adds $10M Venture Funding
Scifiniti, a developer of silicon-based solar materials in San Jose, California secured $10 million in series B venture financing, the second round of funding after initial start-up. Current investors Alloy Ventures, Firelake Capital, I2BF Global Ventures, and Peninsula Ventures took part in the round. The company’s first product is SmartWafer, an alternative photovoltaic solar cell…
-
Celgene, MorphoSys Partner on Multiple Myeloma Antibody
Celgene Corporation, a biopharmaceutical company in Summit, New Jersey, agreed to license technology and invest in the biotechnology company MorphoSys AG in Munich, Germany for commercializing a monoclonal antibody developed by MorphoSys to treat multiple myeloma and some forms of leukemia. The total potential value of the deal, if all contingencies are met, is €628…
-
VC Fund Gains $100M for University, Defense Lab Spinoffs
Allied Minds, a venture capital (VC) company in Boston starting companies that commercialize research from university and U.S. federal labs, raised $100 million for its next series of investments. The company says closing this funding round brings its total assets to about $500 million. Allied Minds makes early-stage investments, sometimes soon after the point of…
-
Biotech Developing Genetics Therapies Gains $101M in IPO
The biotechnology company bluebird bio in Cambridge, Massachusetts developing therapies for genetic disorders raised $101 million through its initial public offering (IPO) of 5.9 million shares priced at $17.00 a share. The company’s stock, trading on the NASDAQ under the code BLUE was priced at $26.00 a share at 11:00 am ET today. bluebird bio…
-
Kidney Disease Technology Start-Up Lands $9.5M Venture Funds
TVA Medical Inc., a developer of devices in Austin, Texas to treat end-stage renal disease, secured $9.5 million in series B venture funds, the second round of financing after initial start-up. Austin-based S3 Ventures, an early-stage venture capital company, led the round with TriStar Technology Ventures and existing investor Santé Ventures. End-stage renal disease occurs…
-
Science Business Content Partner: The Life Sciences Report
Science Business is pleased to offer a new feature, the latest entries from the investment newsletter, The Life Sciences Report, published by Streetwise Reports. The Life Sciences Report features interviews with investment experts in biotechnology, pharmaceuticals, medical devices, and diagnostics. Science Business aims to provide breaking news developments in the science and business of the…
-
AstraZeneca Acquires Respiratory Disease Therapy Developer
The global pharmaceutical company AstraZeneca is buying Pearl Therapeutics in Redwood City, California, a developer of treatments for chronic respiratory diseases. The deal is valued initially at $560 million, but has a total potential value of $1.15 billion, adding in subsequent milestone and royalty payments. The seven year-old Pearl Therapeutics develops small-molecule treatments for chronic…